IN8bio (formerly Incysus Therapeutics, Nasdaq INAB) is a biomedical company specializing in the development of gamma-delta T cell therapies for the treatment of cancer. The business is based on research conducted by Lawrence Lamb at UAB Comprehensive Cancer Center and H. Trent Spencer of the Emory University School of Medicine. Its patents are shared with UAB, Emory University and Children's Healthcare of Atlanta. The company adopted its current name in August 2020. The company went public on the Nasdaq Global Market exchange on July 30, 2021.
Lamb and Spencer were joined in the founding of the business in 2017 by CEO William Ho. Ho maintains a business office for IN8bio on Madison Avenue in New York City. The company's research laboratories, long-time tenants at the Innovation Depot, moved to a 10,439 square-foot space in the Martin Biscuit Building at Pepper Place in 2023. Samantha Youngblood is senior lab manager.
The company is engaged in trials of its gamma-delta T cell immunotherapy treatments for various cancers. UAB's Burt Nabors is lead investigator for the national Phase 1b/2 clinical trial of IMB-400, which targets glioblastoma brain tumors.
- Hansen, Jeff (May 4, 2017) "UAB spinoff targets cancer with drug-resistant immunotherapy, a novel approach to fighting tumors." UAB News
- Van der Bijl, Hanno (January 22, 2021) "IN8bio moving out of Innovation Depot to new space at Pepper Place." Birmingham Business Journal
- "IN8bio launches public offering on Nasdaq." (August 6, 2021) Birmingham Business Journal
- Thrailkill, Laurel (August 6, 2023) "Multimillion-dollar cancer research lab opens in Birmingham." Birmingham Business Journal
- IN8bio website